Vivien Yin, PhD

Dr. Yin is an Associate Member in the Department of Biostatistics and Bioinformatics; before that, she was an Associate Professor in Biostatistics at the Mayo Clinic. Dr. Yin has provided statistical and scientific leadership for several nationally funded cancer research programs: she was the Co-Director of the Biostatistics and Bioinformatics Core for the Mayo Clinic Hepatobiliary Cancer Specialized Program of Research Excellence (SPORE) and the Consortium Statistician for the NCI Experimental Therapeutic Clinical Trial Network (ETCTN) Mayo Clinic Consortium. Currently, she serves as a Lead Faculty Statistician for the Alliance for Clinical Trials in Oncology (an NCI-funded National Clinical Trial Network) and the National Pediatric Cancer Foundation Sunshine Project. Dr Yin works to develop innovative statistical study design to run more efficient clinical trials that deliver effective, novel treatments to cancer patients, including study designs for dose-finding trials, basket and umbrella trials (i.e., master protocols), pragmatic trials with real-world evidence (RWE), and causal artificial intelligence (AI) for enrichment trials. She is nationally recognized as a clinical trial implementation scientist and novel methods developer, and her research contributes to a better understanding of factors directly related to prognosis and treatment of cancer.

Associations

• Biostatistics and Bioinformatics
• Gastrointestinal Oncology
• Molecular Medicine Program

I am fortunate to have collaborated with many outstanding collaborators who are experts in oncology. I have provided statistical and scientific collaboration for several nationally funded cancer clinical trial networks: I am the designated Lead Faculty Statistician for the Leukemia committee of the NCI’s NCTN group Alliance for Clinical Trials in Oncology (2016-present) and I was the Mayo Clinic Consortium Statistician for the NCI’s Experimental Therapeutics Clinical Trial Network (2015-2022). Additionally, I serve as the faculty statistician for the NCI Precision Medicine Initiative MyeloMATCH and for the NCI Head and Neck Rare Tumor Task Force. Currently at the Moffitt Cancer Center, I have the opportunity to collaborate with the department of Radiation Oncology and Health Outcomes and Behavior. Previously at the Mayo Clinic Cancer Center, I was the Co-Director for the Biostatistics and Bioinformatics Core of the Hepatobiliary SPORE (2018-2023), for which I successfully led the biostatistical component of the grant application and the competitive renewal. In my capacity as the primary statistician, I have designed and conducted > 20 cancer clinical trials, many of which utilized innovative designs. I had the opportunity to lead prognostic and predictive modeling using large, completed, international randomized clinical trials and evaluation of clinical and molecular biomarkers in colon cancer, as a co-investigator on two international research groups: the Adjuvant Colon Cancer End Points (ACCENT) Group and the ARCAD (Aide et Recherche en Cancérologie Digestive) Clinical Trials Program. My independent research program is motivated directly by my collaborations in clinical trial research. Recent areas of focus include: 1) adaptive dose-finding designs, 2) basket and umbrella trial (master protocol) designs, 4) evaluation of surrogate endpoints in clinical trials, and 5) causal machine learning for trial enrichment. I have made significant contributions to clinical trials as an implementation scientist and novel methods developer. I have national and international recognition for my work, including professional and institutional awards, research funding from FDA and the Alliance Foundation as PI, editorial board member for Contemporary Clinical Trial and Chinese Clinical Oncology, and national scientific review committees such as NCI Task Force and Clinical Trial Oversight Committee for the National Pediatric Cancer Foundation.

• Rollison DE, Garcia MA, Amorrortu RP, Zhao Y, Mittman B, Turner K, Kirtane K, Soliman H, Byrne MM, Meade C, Gwede CK, Eschrich S, Yin J, Stanley NB, Fuzzell L, Hernandez D, Tapia-Kwan E, Vadaparampil ST. Design of a cluster randomized multi-level intervention to decrease barriers to minority cancer patient referral and enrollment to cancer clinical trials: The ACT WONDER2S study. Contemp Clin Trials. 2025 Nov.158:108096. Pubmedid: 40992541.
• Selukar S, Yin V, Othus M. Synthetic control arms and other uses of external data in clinical trials for hematological malignancies. Blood Rev. 2025 Jul.101324. Pubmedid: 40753019.
• Zhao Y, Amorrortu RP, Hicks JK, Garcia MA, Haura EB, Yin J, Vadaparampil ST, Rollison DE. An examination of factors associated with disparities in clinical trial eligibility guided by the Socioecological Model. Cancer. 2025 Jul.131(13):e35944. Pubmedid: 40530674. Pmcid: PMC12263167.
• Shen S, Yin J. Bayesian mediation analysis using patient-reported outcomes from AI chatbots to infer causal pathways in clinical trials. PLoS One. 2025 Jul.20(7):e0326517. Pubmedid: 40705787. Pmcid: PMC12289003.
• Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Dhrubo D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodriguez-Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real world survival estimation. Res Sq. 2025 Aug. Pubmedid: 40799741. Pmcid: PMC12340904.
• Yin J. Narrative Review of the Use of Genomic-Adjusted Radiation Dose (GARD) in Radiotherapy. Cancers (Basel). 2025 Aug.17(16). Pubmedid: 40867280. Pmcid: PMC12384496.
• Rishi A, Albuquerque KV, Jhingran A, Donovan EK, Horne ZD, Ludwig MS, Pathak P, Goldsberry R, Glaser SM, Garg A, Yin V, Fernandez DC, Beriwal S, Ahmed KA, Montejo ME. Definitive intensity-modulated radiotherapy for organ preservation in vulvar cancer: A multicenter study. Gynecol Oncol. 2025 Aug.199:1-9. Pubmedid: 40513383.
• Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep.195:107928. Pubmedid: 39197359. Pmcid: PMC11416719.
• Dhir A, Hayashi M, Bodlak A, Oesterheld J, Loeb DM, Mascarenhas L, Isakoff MS, Sandler ES, Borinstein SC, Trucco M, Lagmay JP, Setty BA, Pratilas CA, Caywood E, Metts J, Yin H, Fridley B, Yin J, Laborde J, Reed DR, Adams DL, Wagner LM. Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation. Clin Cancer Res. 2024 Dec.30(23):5314-5322. Pubmedid: 39360936.
• Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023 Jan.41(2):336-342. Pubmedid: 35787017. Pmcid: PMC9839232.
• Yin J, Shen S, Shi Q. Challenges, opportunities, and innovative statistical designs for precision oncology trials. Ann Transl Med. 2022 Sep.10(18):1038. Pubmedid: 36267789. Pmcid: PMC9577796.
• Li X, Lu C, Broglio K, Bycott P, Chen J, Jiang Q, Lin J, Ye J, Yin J. Current usage and challenges of master protocols-based on survey results by ASA BIOP oncology methodology working group master protocol sub-team. Ann Transl Med. 2022 Sep.10(18):1036. Pubmedid: 36267733. Pmcid: PMC9577726.
• Ji H, Barr Fritcher EG, Yin J, Bainter TM, Zemla TJ, Gores GJ, Halling KC, Kipp BR, Roberts LR. Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on Prognosis in De Novo Cholangiocarcinoma. Clin Transl Gastroenterol. 2022 Oct.13(10):e00523. Pubmedid: 36000989. Pmcid: PMC9624591.
• Franko J, Yin J, Adams RA, Zalcberg J, Fiskum J, Van Cutsem E, Goldberg RM, Hurwitz H, Bokemeyer C, Kabbinavar F, Curtis A, Meyers J, Chibaudel B, Yoshino T, de Gramont A, Shi Q. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. Eur J Cancer. 2022 Oct.174:142-152. Pubmedid: 35994794.
• Noseworthy PA, Attia ZI, Behnken EM, Giblon RE, Bews KA, Liu S, Gosse TA, Linn ZD, Deng Y, Yin J, Gersh BJ, Graff-Radford J, Rabinstein AA, Siontis KC, Friedman PA, Yao X. Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial. Lancet. 2022 Oct.400(10359):1206-1212. Pubmedid: 36179758.
• Hassan Nelson L, Fuentes-Bayne H, Yin J, Asmus E, Ryder M, Morris JC, Hilger CR, Bible KC, Chintakuntlawar AV, Rao SN. Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. J Endocr Soc. 2022 May.6(5):bvac044. Pubmedid: 35402763. Pmcid: PMC8989149.
• Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga. Hepatol Commun. 2022 May.6(5):1172-1185. Pubmedid: 34783177. Pmcid: PMC9035563.
• Kosari F, Disselhorst M, Yin J, Peikert T, Udell J, Johnson S, Smadbeck J, Murphy S, McCune A, Karagouga G, Desai A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield AS. Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2022 Mar.17(3):446-454. Pubmedid: 34800701. Pmcid: PMC8882146.
• Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun.6(1):e2100274. Pubmedid: 35666960. Pmcid: PMC9200394.
• Muffly L, Yin J, Jacobson S, Wall A, Quiroz E, Advani AS, Luger SM, Tallman MS, Litzow MR, Foster MC, Erba HP, Appelbaum FR, Larson RA, Keegan THM, Stock W. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 Jul.6(14):4085-4092. Pubmedid: 35838753. Pmcid: PMC9327550.
• Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, Bekaii-Saab TS. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol. 2022 Jan.11:794009. Pubmedid: 35083150. Pmcid: PMC8784799.
• Torbenson M, McCabe CE, O'Brien DR, Yin J, Bainter T, Tran NH, Yasir S, Chen ZE, Dhanasekaran R, Ahn KS, Roberts LR, Wang C. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification. Hum Pathol. 2022 Jan.119:15-27. Pubmedid: 34592239. Pmcid: PMC9258524.
• Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022 Jan.114(1):60-67. Pubmedid: 34505880. Pmcid: PMC8755492.
• Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 Feb.40(1):115-123. Pubmedid: 34515877. Pmcid: PMC8766914.
• Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Digest Dis Sci. 2022 Aug.67(8):3797-3805. Pubmedid: 34773565.
• Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 Nov.113(12):1705-1713. Pubmedid: 34061178.
• Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RA. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 Nov.5(22):4691-4700. Pubmedid: 34492682. Pmcid: PMC8759134.
• Montefiori LE, Bendig S, Gu Z, Chen X, Pölönen P, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discov. 2021 Nov.11(11):2846-2867. Pubmedid: 34103329. Pmcid: PMC8563395.
• Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Stat Med. 2021 May.40(12):2893-2921. Pubmedid: 33772843.
• Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol. 2021 Jun.13. Pubmedid: 34262614. Pmcid: PMC8252342.
• Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology. 2021 Jun.73(6):2342-2360. Pubmedid: 33140851. Pmcid: PMC8115767.
• Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 Jan.5(2):504-512. Pubmedid: 33496745. Pmcid: PMC7839367.
• Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, Joyce C, Yin J, Ahmed F, Roberts LR, Qiu W. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep. 2021 Feb.34(8):108765. Pubmedid: 33626345. Pmcid: PMC7954228.
• Pant K, Peixoto E, Richard S, Biswas A, O'Sullivan MG, Giama N, Ha Y, Yin J, Carotenuto P, Salati M, Ren Y, Yang R, Franco B, Roberts LR, Gradilone SA. Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma. Hepatology. 2021 Dec.74(6):3235-3248. Pubmedid: 34322899.
• Yin J, Du Y, Qin R, Shen S, Mandrekar S. phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints. PLoS One. 2021.16(9):e0256391. Pubmedid: 34473708. Pmcid: PMC8412295.
• Carr RM, Duma N, McCleary-Wheeler AL, Almada LL, Marks DL, Graham RP, Smyrk TC, Lowe V, Borad MJ, Kim G, Johnson GB, Allred JB, Yin J, Lim VS, Bekaii-Saab T, Ma WW, Erlichman C, Adjei AA, Fernandez-Zapico ME. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology. 2020 Sep.20(6):1115-1122. Pubmedid: 32778368.
• Gulhati P, Yin J, Pederson L, Schmoll HJ, Hoff P, Douillard JY, Hecht JR, Tournigand C, Tebbut N, Chibaudel B, Gramont A, Shi Q, Overman MJ. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. J Natl Cancer Inst. 2020 Nov.112(11):1127-1136. Pubmedid: 32191317. Pmcid: PMC7669230.
• Yin J, Yuan Y. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials. J Biopharm Stat. 2020 Nov.30(6):1006-1025. Pubmedid: 32966167.
• Du Y, Yin J, Sargent DJ, Mandrekar SJ. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. J Biopharm Stat. 2020 Jun.29(2):271-286. Pubmedid: 30403559. Pmcid: PMC6379115.
• Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr.31(4):480-486. Pubmedid: 32085892. Pmcid: PMC10688027.
• Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 2019 Nov.29(11):1615-1622. Pubmedid: 31595822.
• Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 Jun.3(11):1714-1721. Pubmedid: 31171508. Pmcid: PMC6560345.
• Yin J, Qin R, Sargent DJ, Erlichman C, Shi Q. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. J Biopharm Stat. 2019 Jul.28(3):451-462. Pubmedid: 28448747.
• Boyce JM, Cooper T, Yin J, Li FY, Arbogast JW. Challenges encountered and lessons learned during a trial of an electronic hand hygiene monitoring system. Am J Infect Control. 2019 Dec.47(12):1443-1448. Pubmedid: 31324492.
• Wang F, Molina J, Satele D, Yin J, Lim VS, Adjei AA. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Invest New Drugs. 2019 Aug.37(4):658-665. Pubmedid: 30382439.
• Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M, Lim VS, Kaufmann SH, Adjei A. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Invest New Drugs. 2019 Apr.37(2):307-314. Pubmedid: 30171497. Pmcid: PMC9594493.
• Ruppert AS, Yin J, Davidian M, Tsiatis AA, Byrd JC, Woyach JA, Mandrekar SJ. Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. Ann Oncol. 2019 Apr.30(4):542-550. Pubmedid: 30799502. Pmcid: PMC6735877.
• Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr.133(14):1548-1559. Pubmedid: 30658992. Pmcid: PMC6450431.
• Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD databas. Eur J Cancer. 2018 Nov.103:205-213. Pubmedid: 30268921.
• Yin J, Dahlberg SE, Mandrekar SJ. Evaluation of End Points in Cancer Clinical Trials. J Thorac Oncol. 2018 Jun.13(6):745-747. Pubmedid: 29706308.
• Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017 May.8(21):35326-35338. Pubmedid: 28186961. Pmcid: PMC5471058.
• Yin J, Qin R, Ezzalfani M, Sargent DJ, Mandrekar SJ. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. Stat Med. 2017 Jan.36(1):67-80. Pubmedid: 27633877. Pmcid: PMC5138146.
• Yin J, Paoletti X, Sargent DJ, Mandrekar SJ. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clin Trials. 2017 Dec.14(6):611-620. Pubmedid: 28764555. Pmcid: PMC5714674.
• Yin J, Shen S. Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies. J Biom Biostat. 2016 Dec.7(4). Pubmedid: 28616356. Pmcid: PMC5467542.
• Anand A, Bues M, Rule WG, Keole SR, Beltran CJ, Yin J, Haddock MG, Hallemeier CL, Miller RC, Ashman JB. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Radiother Oncol. 2015 Dec.117(3):505-508. Pubmedid: 26597231.
• Yin J, Reisinger HS, Vander Weg M, Schweizer ML, Jesson A, Morgan DJ, Forrest G, Graham M, Pineles L, Perencevich EN. Establishing evidence-based criteria for directly observed hand hygiene compliance monitoring programs: a prospective, multicenter cohort study. Infect Cont Hosp Ep. 2014 Sep.35(9):1163-1168. Pubmedid: 25111925.
• Ohl M, Dillon D, Moeckli J, Ono S, Waterbury N, Sissel J, Yin J, Neil B, Wakefield B, Kaboli P. Mixed-methods evaluation of a telehealth collaborative care program for persons with HIV infection in a rural setting. J Gen Intern Med. 2013 Sep.28(9):1165-1173. Pubmedid: 23475640. Pmcid: PMC3744312.
• Reisinger HS, Yin J, Radonovich L, Knighton VT, Martinello RA, Hodgson MJ, Perencevich E. Comprehensive survey of hand hygiene measurement and improvement practices in the Veterans Health Administration. Am J Infect Control. 2013 Nov.41(11):989-993. Pubmedid: 23932826.
• Yin J, Schweizer ML, Herwaldt LA, Pottinger JM, Perencevich EN. Benefits of universal gloving on hospital-acquired infections in acute care pediatric units. Pediatrics. 2013 May.131(5):e1515-e1520. Pubmedid: 23610206.
• Li Y, Cai X, Yin J, Glance LG, Mukamel DB. Is higher volume of postacute care patients associated with a lower rehospitalization rate in skilled nursing facilities?. Med Care Res Rev. 2012 Feb.69(1):103-118. Pubmedid: 21810798. Pmcid: PMC3785004.
• Li Y, Glance LG, Yin J, Mukamel DB. Racial disparities in rehospitalization among Medicare patients in skilled nursing facilities. Am J Public Health. 2011 May.101(5):875-882. Pubmedid: 21421957. Pmcid: PMC3076407.
• Li Y, Yin J, Cai X, Temkin-Greener J, Mukamel DB. Association of race and sites of care with pressure ulcers in high-risk nursing home residents. Jama. 2011 Jul.306(2):179-186. Pubmedid: 21750295. Pmcid: PMC4108174.

• Title: Novel master protocol designs for precision oncology trials in pediatric and rare cancers
  Award Number: 25C39
  Sponsor: Florida Department of Health
  Yin, J. (PD/PI)
• Title: Alliance Statistics and Data Management Center
  Award Number: 3U10CA180882-11S1
  Sponsor: National Cancer Institute (NCI)
  Yin, J. (PD/PI)
• Title: Overcoming Metastatic Spread of Osteosarcoma with RNA Loaded Nanoparticles
  Award Number: 5R01CA266857-02
  Sponsor: National Cancer Institute (NCI)
  Yin, J. (PD/PI)
• Title: Bayesian Adaptive Basket Trial Designs for Neoantigen Based Immunotherapy with Borrowing Strength Across Subpopulations Within the Trial and From External Controls
  Award Number: 5U01FD005938-07
  Sponsor: US Food & Drug Administration (FDA)
  Yin, J. (PD/PI)